How to Get Rezdiffra (Resmetirom) in Texas

What Is Rezdiffra and Why Does It Matter for Texas Patients?

Rezdiffra (resmetirom) is a thyroid hormone receptor beta (THR-β) selective agonist and the first FDA-approved pharmacotherapy for MASH with moderate-to-advanced hepatic fibrosis (stages F2 and F3). The FDA granted accelerated approval in March 2024 based on surrogate histological endpoints from the MAESTRO-NASH trial.

Texas carries a disproportionate MASH burden. The state's obesity prevalence exceeds 36% in adults, and its large Hispanic population faces elevated genetic susceptibility through PNPLA3 polymorphisms. Before resmetirom, no approved drug existed to address fibrotic progression in these patients. Lifestyle intervention alone achieves the ≥10% weight loss threshold needed to reverse fibrosis in fewer than 10% of patients outside structured trial settings [1].

The practical question for Texas patients and clinicians is straightforward: how do you actually get the prescription filled, covered, and delivered? The answer depends on prescriber type, insurance carrier, and pharmacy channel.

MAESTRO-NASH Trial Results: The Evidence Behind the Prescription

The MAESTRO-NASH phase 3 trial (N=966) randomized adults with biopsy-confirmed NASH and fibrosis stages F1B through F3 to resmetirom 80 mg, 100 mg, or placebo once daily. At 52 weeks, 25.9% of patients receiving 80 mg achieved fibrosis improvement by at least one stage with no worsening of NASH, compared with 14.2% on placebo (P<0.001). The 100 mg group showed 29.9% achieving this dual endpoint [2].

NASH resolution without worsening of fibrosis occurred in 29.9% of the 80 mg arm and 9.7% of placebo recipients. LDL cholesterol dropped by approximately 14% from baseline. These histological and cardiometabolic improvements represent the data package that Texas prescribers reference when justifying prior authorization requests.

"Resmetirom addresses a mechanism distinct from weight loss. It directly activates hepatic THR-β to restore mitochondrial fatty acid oxidation," stated Dr. Stephen Harrison, hepatologist and MAESTRO-NASH investigator, in the NEJM publication [2].

Who Can Prescribe Rezdiffra in Texas?

Any Texas-licensed prescriber with appropriate scope of practice can write a resmetirom prescription. This includes physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). Texas grants NPs independent practice authority after completing a collaborative practice period, and PAs prescribe under physician delegation.

In practice, most Rezdiffra prescriptions originate from hepatologists, gastroenterologists, or endocrinologists who have access to liver biopsy or non-invasive fibrosis staging. Primary care physicians can also prescribe if they document fibrosis severity through validated tools like FibroScan (vibration-controlled transient elastography) or the FIB-4 index combined with enhanced liver fibrosis (ELF) testing [3].

Specialty prescribers at major Texas academic centers (UT Southwestern, Baylor College of Medicine, MD Anderson) have established Rezdiffra prescribing protocols. Community gastroenterologists across Houston, Dallas-Fort Worth, San Antonio, and Austin have also begun initiating therapy as awareness of the approval grows.

Telehealth Access to Rezdiffra in Texas

Texas permits telehealth prescribing of Rezdiffra. The state's telehealth parity law (SB 1107) requires insurers to cover telemedicine services equivalent to in-person visits, and the Texas Medical Board allows prescribing through audiovisual encounters when a legitimate provider-patient relationship exists [4].

Several hepatology-focused telehealth platforms now serve Texas patients. The process typically follows this sequence:

1. Patient completes intake with relevant labs and imaging
2. Synchronous video consultation with a licensed Texas prescriber
3. Prescriber reviews fibrosis documentation and confirms MASH diagnosis
4. Electronic prescription transmitted to specialty pharmacy

The telehealth pathway works best for patients who already have FibroScan or biopsy results. Patients without existing fibrosis documentation may need an initial in-person visit for elastography before the telehealth prescriber can confirm eligibility. Some telehealth platforms coordinate FibroScan appointments at partner imaging centers in major Texas metros.

Wait times for telehealth hepatology appointments in Texas range from 3 to 14 days, compared with 6 to 12 weeks for in-person hepatology referrals at academic centers. This gap makes telehealth a practical first step for patients who suspect they qualify.

Required Labs Before Starting Rezdiffra in Texas

Before any Texas prescriber initiates resmetirom, baseline laboratory and imaging work must confirm both the diagnosis and safety for treatment. The standard pre-prescribing workup includes:

Diagnostic confirmation:

• Liver biopsy with NASH Activity Score (NAS) ≥4 and fibrosis stage F2 or F3, OR
• FibroScan with controlled attenuation parameter (CAP) ≥280 dB/m and liver stiffness ≥8.0 kPa (suggesting ≥F2), combined with elevated ALT and metabolic risk factors

Safety labs:

• Comprehensive metabolic panel (CMP) including AST, ALT, albumin, bilirubin, and platelets
• Thyroid function (TSH, free T4). Resmetirom is THR-β selective but prescribers monitor for any thyroid axis perturbation
• Lipid panel (LDL reduction is expected and can guide co-medication adjustment)
• Complete blood count
• INR/PT if cirrhosis is suspected

Exclusion criteria to rule out:

• Decompensated cirrhosis (Child-Pugh B or C)
• Active hepatitis B or C infection
• Concurrent use of strong CYP2C8 inhibitors

The FDA prescribing information specifies periodic monitoring of liver chemistries during treatment. Most Texas prescribers recheck ALT and AST at 4 weeks, 12 weeks, and quarterly thereafter [5].

Insurance Coverage and Prior Authorization in Texas

Commercial insurance plans in Texas generally require prior authorization for Rezdiffra. The documentation package that Texas insurers expect includes:

• Confirmed MASH diagnosis with histological or non-invasive evidence of F2-F3 fibrosis
• Documentation that lifestyle modifications were attempted (typically ≥6 months of diet and exercise counseling)
• Relevant labs showing metabolic syndrome features (elevated ALT, insulin resistance markers)
• Prescriber attestation of the specific fibrosis stage
• Failure of, intolerance to, or ineligibility for alternative treatments (though no FDA-approved alternatives currently exist for MASH, some insurers still request this)

Texas Medicaid: does not cover Rezdiffra for MASH as an isolated indication. Coverage is limited to patients with comorbid type 2 diabetes under certain formulary pathways. This leaves a significant coverage gap for Medicaid beneficiaries with MASH alone.

Medicare Part D: coverage varies by plan. Several Part D plans have added resmetirom to specialty tiers (Tier 5) with coinsurance of 25-33%. Madrigal Pharmaceuticals operates a patient assistance program (Rezdiffra Access Solutions) that may reduce out-of-pocket costs for eligible patients [6].

Prior authorization turnaround in Texas typically takes 5 to 15 business days for commercial plans. Denied claims can be appealed through the Texas Department of Insurance external review process.

Pharmacy Options: Specialty and 503A Compounding in Texas

Rezdiffra distributes primarily through specialty pharmacies. Madrigal's limited distribution network includes national specialty pharmacy chains with Texas operations. Patients can receive the medication through:

Specialty pharmacy (branded product):

• Ships directly to patient or prescriber office
• Handles prior authorization coordination
• Provides adherence support programs
• Major specialty pharmacies operating in Texas include Accredo, CVS Specialty, and Optum Specialty

503A compounding pharmacies in Texas:

• Texas State Board of Pharmacy licenses 503A facilities under strict oversight
• Compounded resmetirom may be available for patients with specific formulation needs (e.g., dye allergies, swallowing difficulties)
• 503A pharmacies compound pursuant to individual prescriptions and can ship within Texas
• The Texas State Board of Pharmacy enforces compliance with USP 795 standards for non-sterile compounding

A compounded version is not therapeutically interchangeable with branded Rezdiffra without prescriber authorization. Patients considering this route should discuss bioequivalence considerations with their hepatologist.

Most Texas patients receiving branded Rezdiffra through specialty pharmacy report delivery within 5 to 10 business days after prior authorization approval. Expedited shipping options exist for patients with urgent clinical need documented by the prescriber.

Step-by-Step: Getting Rezdiffra in Texas

The complete pathway from initial concern to medication in hand follows a predictable sequence for Texas residents:

Week 1-2: Obtain fibrosis staging. Schedule FibroScan at a Texas imaging center or gastroenterology office. If results suggest ≥F2, proceed. Cost without insurance: approximately $150-400.

Week 2-3: Consult a prescriber. Book a telehealth hepatology visit or in-person appointment. Bring FibroScan results, recent labs, and metabolic history.

Week 3-4: Prescriber submits prior authorization. The specialty pharmacy or prescriber's office assembles the documentation package and submits to your insurer.

Week 4-6: Prior authorization decision. If approved, the specialty pharmacy processes the prescription. If denied, the prescriber files a peer-to-peer review or formal appeal.

Week 5-7: Medication delivery. Specialty pharmacy ships to your home or pickup location in Texas.

Total elapsed time from first appointment to medication receipt: approximately 3 to 7 weeks for straightforward cases. Complex cases involving appeals can extend to 10-12 weeks.

Cost Considerations Without Insurance

The wholesale acquisition cost (WAC) for Rezdiffra runs approximately $47,400 per year at the 100 mg daily dose. Cash-pay patients face significant financial barriers. Options to reduce cost include:

• Madrigal's patient assistance program for uninsured or underinsured patients
• Manufacturer copay cards reducing commercial insurance copays to as low as $0 for eligible patients
• 503A compounding (pricing varies; typically lower than branded WAC but without manufacturer copay support)
• Clinical trial enrollment. Active trials evaluating resmetirom in expanded populations may accept Texas patients through sites at UT Southwestern and Houston Methodist [7]

The AASLD practice guidance on MASLD recommends considering pharmacotherapy cost in shared decision-making, particularly for patients with F2 fibrosis where progression risk is lower than F3 [3].

Transferring a Rezdiffra Prescription to Texas

Patients relocating to Texas or seeking to fill an out-of-state prescription face specific regulatory steps. Texas accepts transferred prescriptions from other states provided:

• The original prescriber holds an active license (does not need to be Texas-licensed for a one-time transfer)
• The receiving Texas pharmacy verifies the prescription's validity
• Prior authorization is re-initiated with the patient's Texas-based insurance plan (out-of-state PAs do not transfer)

Patients moving to Texas should request their hepatologist send records (including fibrosis staging documentation) to a new Texas-based provider who can assume ongoing prescribing and monitoring. Specialty pharmacies with national footprints can often coordinate the geographic transition internally.

Monitoring and Follow-Up Requirements in Texas

Once on Rezdiffra, Texas patients require ongoing monitoring that any licensed prescriber can perform:

• Liver chemistries (AST, ALT) at weeks 4 and 12, then every 3 months
• Lipid panel at 12 weeks (LDL typically decreases 10-15%)
• Thyroid function at 6 months if clinically indicated
• Repeat fibrosis assessment (FibroScan or ELF panel) at 12 months to confirm treatment response

The MAESTRO-NASH protocol assessed histological response at 52 weeks via repeat biopsy [2]. In clinical practice, most Texas hepatologists use non-invasive surrogates (improvement in liver stiffness measurement, normalization of ALT) to judge treatment continuation rather than mandating repeat biopsy.

Prescribers should reassess at 12 months whether fibrosis has stabilized or improved. If no measurable benefit appears on non-invasive testing, discontinuation and consideration of alternative management is appropriate per emerging expert consensus.